When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy,
fixed doses were recommended by the manufacturer. Awareness of the potential for a more …

Successful solid organ transplantation reflects meticulous attention to the details of
immunosuppression, balancing risks for graft rejection against risks for infection. The “net …

Background Long-term immunosuppressive treatment does not efficiently prevent relapses
of lupus nephritis (LN). This investigator-initiated randomised trial tested whether …

Abstract Model-informed precision dosing (MIPD) stands as a significant development in
personalized medicine to tailor drug dosing to individual patient characteristics. MIPD moves …

With the increasing use of mycophenolic acid (MPA) in solid organ transplantation, the need
for more accurate drug dosing has become evident. Personalized immunosuppressive …

This review aims to provide an update of the literature on the pharmacology and toxicology
of mycophenolate in solid organ transplant recipients. Mycophenolate is now the …

Background Computerized physician order entry and clinical decision support systems are
electronic prescribing strategies that are increasingly used to improve patient safety …

Background. Fixed-dose mycophenolate mofetil (MMF) reduces the incidence of acute
rejection after solid organ transplantation. The Fixed-Dose Concentration Controlled trial …

Mycophenolate mofetil (MMF) was developed with cyclosporine as a fixed-dose
immunosuppressant. More recent data indicate a relationship between mycophenolic acid …

The goal of this study was to determine the roles of the organic anion–transporting
polypeptides (OATPs) OATP1A2, OATP1B1, and OATP1B3 and their genetic variants in the …